Biocartis Group NV 2020 AR2
The Biocartis Annual Report 2020 highlights the company's resilience and growth despite the COVID-19 pandemic. Biocartis increased its commercial cartridge volume by 31% to 230,000 cartridges and expanded its installed base to 1,581 Idylla instruments. Financially, product sales revenues grew by 32% to EUR 31.9 million, and total operating income rose by 47% to EUR 55.6 million. Strategically, the company expanded into infectious diseases with the launch of its first pandemic test menu, including the Idylla SARS-CoV-2 Test and SeptiCyte RAPID on Idylla. Additionally, Biocartis strengthened its oncology partnerships with AstraZeneca and Bristol-Myers Squibb.
Company: Biocartis Group NV
Sector: Manufacturing
Country: Belgium
Year: 2020
Type: AR2
Pages: 136
Back to company
Biocartis Group NV
Annual Report
The Biocartis Annual Report 2020 highlights the company's resilience and growth despite the COVID-19 pandemic. Biocartis increased its commercial cartridge volume by 31% to 230,000 cartridges and expanded its installed base to 1,581 Idylla instruments. Financially, product sales revenues grew by 32% to EUR 31.9 million, and total operating income rose by 47% to EUR 55.6 million. Strategically, the company expanded into infectious diseases with the launch of its first pandemic test menu, including the Idylla SARS-CoV-2 Test and SeptiCyte RAPID on Idylla. Additionally, Biocartis strengthened its oncology partnerships with AstraZeneca and Bristol-Myers Squibb.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Jan 1, 2020 - Dec 31, 2020
Fiscal Year
2020
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Workplace Fatalities
Employees